Clinical Trial
doi: 10.1016/j.psychres.2009.03.020.
Epub 2009 Dec 31.
Absence of weight gain association with the HTR2C -759C/T polymorphism in patients with schizophrenia treated with iloperidone
Affiliations
- PMID: 20045196
- DOI: 10.1016/j.psychres.2009.03.020
Item in Clipboard
Clinical Trial
Absence of weight gain association with the HTR2C -759C/T polymorphism in patients with schizophrenia treated with iloperidone
Psychiatry Res.
.
Abstract
Weight gain is a common side effect of antipsychotics, contributing to poor treatment adherence, and previously linked to the -759C/T polymorphism near the serotonin receptor 2C gene. The effect of this polymorphism was analyzed in schizophrenia patients treated with iloperidone for up to 7 months. No association was detected with the modest weight changes observed in these patients.
2009 Elsevier Ltd. All rights reserved.
Similar articles
-
[Association of antipsychotic agent-induced weight gain with a polymorphism of the promotor region of the 5-HT2C receptor gene].Zhonghua Yi Xue Za Zhi. 2002 Aug 25;82(16):1097-101. Zhonghua Yi Xue Za Zhi. 2002. PMID: 12425817 Chinese.
-
[Association of HTR2C-759C/T and -697G/C polymorphisms with antipsychotic agent-induced weight gain].Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2008 Apr;33(4):312-5. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2008. PMID: 18460774 Chinese.
-
-759 C/T polymorphism of 5-HT2C receptor gene and early phase weight gain associated with antipsychotic drug treatment.Prog Neuropsychopharmacol Biol Psychiatry. 2007 Apr 13;31(3):673-7. doi: 10.1016/j.pnpbp.2006.12.021. Epub 2007 Jan 12. Prog Neuropsychopharmacol Biol Psychiatry. 2007. PMID: 17275977 Clinical Trial.
-
[Antipsychotic-induced weight gain--pharmacogenetic studies].Psychiatr Pol. 2006 Sep-Oct;40(5):1009-20. Psychiatr Pol. 2006. PMID: 17217242 Review. Polish.
-
Iloperidone: a new option for the treatment of schizophrenia.Expert Rev Neurother. 2009 Dec;9(12):1727-41. doi: 10.1002/pmic.200800563. Expert Rev Neurother. 2009. PMID: 19951132 Review.
Cited by
-
Iloperidone in the treatment of schizophrenia: an evidence-based review of its place in therapy.Core Evid. 2016 Dec 14;11:49-61. doi: 10.2147/CE.S114094. eCollection 2016. Core Evid. 2016. PMID: 28008301 Free PMC article. Review.
-
Assessment of pharmacotherapy for negative symptoms of schizophrenia.Curr Psychiatry Rep. 2010 Dec;12(6):563-71. doi: 10.1007/s11920-010-0148-0. Curr Psychiatry Rep. 2010. PMID: 20821286 Review.
-
Pharmacogenetics and antipsychotics: therapeutic efficacy and side effects prediction.Expert Opin Drug Metab Toxicol. 2011 Jan;7(1):9-37. doi: 10.1517/17425255.2011.532787. Expert Opin Drug Metab Toxicol. 2011. PMID: 21162693 Free PMC article. Review.
-
Body weight and metabolic adverse effects of asenapine, iloperidone, lurasidone and paliperidone in the treatment of schizophrenia and bipolar disorder: a systematic review and exploratory meta-analysis.CNS Drugs. 2012 Sep 1;26(9):733-59. doi: 10.2165/11634500-000000000-00000. CNS Drugs. 2012. PMID: 22900950
-
Association of the HTR2C-759C/T polymorphism and antipsychotic-induced weight gain: a meta-analysis.Gen Psychiatr. 2020 May 14;33(3):e100192. doi: 10.1136/gpsych-2020-100192. eCollection 2020. Gen Psychiatr. 2020. PMID: 32478286 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
